New developments in topical psoriasis therapy

Shanthi M. Colaco; Sarah Fitzmaurice; Emily Becker; Lawrence C.C. Cheung; John Y.M. Koo; Chai Sue Lee; Priya Sivanesan; Farah Malick; Julie A. Letsinger

New developments in topical psoriasis therapy

Shanthi M. Colaco, Sarah Fitzmaurice, Emily Becker, Lawrence C.C. Cheung, John Y.M. Koo, Chai Sue Lee, Priya Sivanesan, Farah Malick, Julie A. Letsinger

Research output: Chapter in Book/Report/Conference proceeding › Chapter

3 Scopus citations

Abstract

There have not been many new developments in topical therapies for psoriasis in the past few years. One of the few new topical agents, for the scalp, that was recently approved by the United States Food and Drug Administration is a fixed-dose formulation of 0.064% betamethasone dipropionate and 0.005% calcipotriene suspension (Taclonex Scalp®). The ointment formulation of this fixed-dose therapy has been available for some years and is discussed separately in Chapter 6 of this text. In this chapter, in addition to the fixed-dose betamethasone/calcipotriene scalp formulation, we will discuss other new topical psoriatic therapies. These therapies include a new spray formulation of clobetasol propionate 0.05% (Clobex® Spray), clobetasol propionate 0.05% shampoo (Clobex® Shampoo), and clobetasol propionate 0.05% lotion (Clobex Lotion), as well as hydrogel patch.

Original language	English (US)
Title of host publication	Mild-to-Moderate Psoriasis, Second Edition
Publisher	CRC Press
Pages	165-181
Number of pages	17
ISBN (Electronic)	9781420088618
ISBN (Print)	9781420088601
State	Published - Jan 1 2008
Externally published	Yes

ASJC Scopus subject areas

General Medicine

Cite this

@inbook{0cade373c85d4c9e8dfa6b06861c3ded,

title = "New developments in topical psoriasis therapy",

abstract = "There have not been many new developments in topical therapies for psoriasis in the past few years. One of the few new topical agents, for the scalp, that was recently approved by the United States Food and Drug Administration is a fixed-dose formulation of 0.064% betamethasone dipropionate and 0.005% calcipotriene suspension (Taclonex Scalp{\textregistered}). The ointment formulation of this fixed-dose therapy has been available for some years and is discussed separately in Chapter 6 of this text. In this chapter, in addition to the fixed-dose betamethasone/calcipotriene scalp formulation, we will discuss other new topical psoriatic therapies. These therapies include a new spray formulation of clobetasol propionate 0.05% (Clobex{\textregistered} Spray), clobetasol propionate 0.05% shampoo (Clobex{\textregistered} Shampoo), and clobetasol propionate 0.05% lotion (Clobex Lotion), as well as hydrogel patch.",

author = "Colaco, {Shanthi M.} and Sarah Fitzmaurice and Emily Becker and Cheung, {Lawrence C.C.} and Koo, {John Y.M.} and Lee, {Chai Sue} and Priya Sivanesan and Farah Malick and Letsinger, {Julie A.}",

note = "Publisher Copyright: {\textcopyright} 2009 by Informa Healthcare USA, Inc.",

year = "2008",

month = jan,

day = "1",

language = "English (US)",

isbn = "9781420088601",

pages = "165--181",

booktitle = "Mild-to-Moderate Psoriasis, Second Edition",

publisher = "CRC Press",

}

TY - CHAP

T1 - New developments in topical psoriasis therapy

AU - Colaco, Shanthi M.

AU - Fitzmaurice, Sarah

AU - Becker, Emily

AU - Cheung, Lawrence C.C.

AU - Koo, John Y.M.

AU - Lee, Chai Sue

AU - Sivanesan, Priya

AU - Malick, Farah

AU - Letsinger, Julie A.

PY - 2008/1/1

Y1 - 2008/1/1

N2 - There have not been many new developments in topical therapies for psoriasis in the past few years. One of the few new topical agents, for the scalp, that was recently approved by the United States Food and Drug Administration is a fixed-dose formulation of 0.064% betamethasone dipropionate and 0.005% calcipotriene suspension (Taclonex Scalp®). The ointment formulation of this fixed-dose therapy has been available for some years and is discussed separately in Chapter 6 of this text. In this chapter, in addition to the fixed-dose betamethasone/calcipotriene scalp formulation, we will discuss other new topical psoriatic therapies. These therapies include a new spray formulation of clobetasol propionate 0.05% (Clobex® Spray), clobetasol propionate 0.05% shampoo (Clobex® Shampoo), and clobetasol propionate 0.05% lotion (Clobex Lotion), as well as hydrogel patch.

AB - There have not been many new developments in topical therapies for psoriasis in the past few years. One of the few new topical agents, for the scalp, that was recently approved by the United States Food and Drug Administration is a fixed-dose formulation of 0.064% betamethasone dipropionate and 0.005% calcipotriene suspension (Taclonex Scalp®). The ointment formulation of this fixed-dose therapy has been available for some years and is discussed separately in Chapter 6 of this text. In this chapter, in addition to the fixed-dose betamethasone/calcipotriene scalp formulation, we will discuss other new topical psoriatic therapies. These therapies include a new spray formulation of clobetasol propionate 0.05% (Clobex® Spray), clobetasol propionate 0.05% shampoo (Clobex® Shampoo), and clobetasol propionate 0.05% lotion (Clobex Lotion), as well as hydrogel patch.

UR - http://www.scopus.com/inward/record.url?scp=85042265534&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042265534&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:85042265534

SN - 9781420088601

SP - 165

EP - 181

BT - Mild-to-Moderate Psoriasis, Second Edition

PB - CRC Press

ER -

New developments in topical psoriasis therapy

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this